Al­ny­lam slammed af­ter pa­tient death forces in­ves­ti­ga­tors to halt dos­ing of fi­tusir­an, rais­ing new safe­ty fears

Al­ny­lam $AL­NY has been slammed by an­oth­er round of safe­ty fears, forced to sus­pend all treat­ment with fi­tusir­an af­ter a pa­tient died from a blood clot in a Phase II he­mo­phil­ia A study.

Al­ny­lam ex­ecs plan to re­sume dos­ing as soon as pos­si­ble, but the com­pa­ny has been hob­bled by deaths be­fore that re­cent­ly KO’d a top pro­gram at the RNAi group. New safe­ty ques­tions about a key late-stage drug like this is the last thing that Al­ny­lam wants to grap­ple with now.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.